Why Representation Matters in Lung Cancer Clinical Trials

Dec 11, 2022 | 0 comments

The experience of a medical practitioner diagnosed with stage four lung cancer proves how important representation is in clinical trials. When left with the option of clinical trials as her treatment options, she jumped at the chance.

Clinical trial enrollment leaves patients exposed to cutting-edge therapies. However, there is always the risk of not benefiting from the therapies. Sadly, many black patients diagnosed with lung cancer are underrepresented in these clinical trials. Research shows that the number of blacks in these trials has been very low. 

Despite making up about 14 percent of the American Population, blacks only get about 3 percent representation in these clinical trials. In addition, some years experienced a decline in the number of blacks represented.

However, the  American Lung Association, in January 2022, sought to empower the Black community to attract a higher representation. This is achieved by participants sharing their testimonials after going through these trials. The aim is to boost confidence among the black population to participate in these trials. 

Although the chances of getting better after trial treatments are not guaranteed, participants have nothing to lose. Many can manage their cancers through these revolutionary therapies, and those suffering should be encouraged to try them.

Are you 21 or older? This website requires you to be 21 years of age or older. Please verify your age to view the content, or click "Exit" to leave.